<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831892</url>
  </required_header>
  <id_info>
    <org_study_id>I20-ISO1</org_study_id>
    <nct_id>NCT04831892</nct_id>
  </id_info>
  <brief_title>The Effect of Isosorbide Diesters Based Moisturizer on Skin Health</brief_title>
  <official_title>The Effect of Isosorbide Diesters Based Moisturizer on Skin Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Skin Science and Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sytheon Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrative Skin Science and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to assess how a natural ingredient, isosorbide&#xD;
      diesters (IDEAS), works in association with colloidal oatmeal for eczema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The topical therapy of eczema largely focuses on the use of topical medications but there is&#xD;
      demand for topical moisturizers and ingredients that can reduce the need for topical&#xD;
      steroids. The goal of this study is to assess the use of a natural ingredient, isosorbide&#xD;
      diesters (IDEAS), for eczema and if it can reduce the need for the use of topical steroids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 7, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SCORAD</measure>
    <time_frame>4 weeks</time_frame>
    <description>Eczema severity is assessed using the SCORing Atopic Dermatitis validated scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EASI score</measure>
    <time_frame>Week 4</time_frame>
    <description>Eczema severity is assessed using the Eczema Area and Severity Index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EASI score</measure>
    <time_frame>Week 1</time_frame>
    <description>Eczema severity is assessed using the Eczema Area and Severity Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EASI score</measure>
    <time_frame>Week 5</time_frame>
    <description>Eczema severity is assessed using the Eczema Area and Severity Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORAD</measure>
    <time_frame>Week 1</time_frame>
    <description>Eczema severity is assessed using the SCORing Atopic Dermatitis validated scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORAD</measure>
    <time_frame>Week 5</time_frame>
    <description>Eczema severity is assessed using the SCORing Atopic Dermatitis validated scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IVAS</measure>
    <time_frame>Week 1</time_frame>
    <description>Itch severity is assessed using the Itch Visual Analog Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IVAS</measure>
    <time_frame>Week 4</time_frame>
    <description>Itch severity is assessed using the Itch Visual Analog Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IVAS</measure>
    <time_frame>Week 5</time_frame>
    <description>Itch severity is assessed using the Itch Visual Analog Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TEWL</measure>
    <time_frame>Week 1</time_frame>
    <description>Transepidermal water loss (TEWL) is measured with a skin vapometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TEWL</measure>
    <time_frame>Week 4</time_frame>
    <description>Transepidermal water loss (TEWL) is measured with a skin vapometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TEWL</measure>
    <time_frame>Week 5</time_frame>
    <description>Transepidermal water loss (TEWL) is measured with a skin vapometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin hydration level</measure>
    <time_frame>Week 1</time_frame>
    <description>Skin hydration levels are measured using a moisture meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin hydration level</measure>
    <time_frame>Week 4</time_frame>
    <description>Skin hydration levels are measured using a moisture meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin hydration level</measure>
    <time_frame>Week 5</time_frame>
    <description>Skin hydration levels are measured using a moisture meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin pH level</measure>
    <time_frame>Week 1</time_frame>
    <description>Skin pH levels are measured using a skin pH meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin pH level</measure>
    <time_frame>Week 4</time_frame>
    <description>Skin pH levels are measured using a skin pH meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin pH level</measure>
    <time_frame>Week 5</time_frame>
    <description>Skin pH levels are measured using a skin pH meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI survey responses</measure>
    <time_frame>Week 1</time_frame>
    <description>Self-reported quality of life through the Dermatology Life Quality Index, a survey completed by subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI survey responses</measure>
    <time_frame>Week 4</time_frame>
    <description>Self-reported quality of life through the Dermatology Life Quality Index, a survey completed by subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI survey responses</measure>
    <time_frame>Week 5</time_frame>
    <description>Self-reported quality of life through the Dermatology Life Quality Index, a survey completed by subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical lotion containing isosorbide diesters and colloidal oatmeal to be applied to the entire body once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moisturizer containing colloidal oatmeal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical moisturizer with colloidal oatmeal to be applied to the entire body once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal</intervention_name>
    <description>Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)</description>
    <arm_group_label>Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moisturizer containing Colloidal Oatmeal only</intervention_name>
    <description>Vehicle lotion containing 0.1% colloidal oatmeal.</description>
    <arm_group_label>Moisturizer containing colloidal oatmeal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 or over&#xD;
&#xD;
          -  Subjects with a diagnosis of mild to moderate eczema with a SCORAD between 1-50.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who have a known allergy to isosorbide diesters.&#xD;
&#xD;
          -  Individuals who have solely hand and/or foot eczema without evidence of eczema&#xD;
             anywhere else on their body.&#xD;
&#xD;
          -  Individuals who have been on topical calcineurin inhibitors or crisaborole to the&#xD;
             predetermined areas within two weeks of initiation of participation or unwilling to&#xD;
             undergo a washout period.&#xD;
&#xD;
          -  Subjects with an ongoing secondary infection of the skin.&#xD;
&#xD;
          -  Subjects who are on systemic therapy or who need systemic therapy at the discretion of&#xD;
             the investigator. Systemic therapies include cyclosporine, systemic steroids,&#xD;
             methotrexate, and dupilumab. Subjects who have been on cyclosporine, systemic&#xD;
             steroids, or methotrexate in the month prior to initiation of study intervention or&#xD;
             are unwilling to undergo a washout period. Subjects who have been on dupilumab in two&#xD;
             months prior to initiation of study intervention or are unwilling to undergo a washout&#xD;
             period.&#xD;
&#xD;
          -  Subjects with a diagnosis of Scabies.&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raja Sivamani, M.D.</last_name>
    <phone>916-524-1216</phone>
    <email>raja.sivamani@integrativeskinresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Integrative Skin Science and Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Raja Sivamani, M.D.</last_name>
      <phone>916-524-1216</phone>
      <email>raja.sivamani@integrativeskinresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Integrative Skin Science and Research</investigator_affiliation>
    <investigator_full_name>Raja Sivamani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>eczema</keyword>
  <keyword>skin</keyword>
  <keyword>dermatology</keyword>
  <keyword>isosorbide diesters</keyword>
  <keyword>skin microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

